Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease

Table 2 Developmental status of pattern recognition receptor antagonists for potential use as therapeutics

Compound	Target	Drug class	Indications	Company	Clinical phase
NI-0101	TLR4	Antibody	RA	Novimmune	Phase I
Chaperonin 10/X Toll	TLR4	Protein	RA, psoriasis, MS	Cbio Ltd	Phase II
VTX-763	TLR8	Small molecule	Autoimmune disorders	VentiRx Pharmaceuticals	Pre-clinical
CRID3	NLRP3	Small molecule		Amgen	Pre-clinical
OPN-305	TLR2	Antibody	Ischaemia reperfusion injury	Opsona Therapeutics	Phase I
IMO-3100	TLR7/TLR9	DNA-based small molecule	Psoriasis	Idera pharmaceuticals	Phase II
DV1179	TLR7/TLR9	Small molecule	SLE	Dynavax	Phase II
CPG52364	TLR7/TLR9	Small molecule	SLE	Pfizer	Phase II

MS, multiple sclerosis; NLR, nucleotide-binding oligomerization domain-like receptor; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TLR, Toll-like receptor.

ISSN: 1478-6362